96 related articles for article (PubMed ID: 24342820)
1. A two-stage patient enrichment adaptive design in phase II oncology trials.
Song JX
Contemp Clin Trials; 2014 Jan; 37(1):148-54. PubMed ID: 24342820
[TBL] [Abstract][Full Text] [Related]
2. Design and endpoints of clinical trials in hepatocellular carcinoma.
Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
[TBL] [Abstract][Full Text] [Related]
3. A Bayesian adaptive design for multi-dose, randomized, placebo-controlled phase I/II trials.
Xie F; Ji Y; Tremmel L
Contemp Clin Trials; 2012 Jul; 33(4):739-48. PubMed ID: 22426247
[TBL] [Abstract][Full Text] [Related]
4. The use of phase 2 interim analysis to expedite drug development decisions.
Huang J; Das A; Burger HU; Zhong W; Zhang W; Lieberman G
Contemp Clin Trials; 2014 Jul; 38(2):235-44. PubMed ID: 24854415
[TBL] [Abstract][Full Text] [Related]
5. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma.
Shao YY; Lin ZZ; Hsu C; Shen YC; Hsu CH; Cheng AL
Cancer; 2010 Oct; 116(19):4590-6. PubMed ID: 20572033
[TBL] [Abstract][Full Text] [Related]
6. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.
Schmidli H; Bretz F; Racine-Poon A
Stat Med; 2007 Nov; 26(27):4925-38. PubMed ID: 17590875
[TBL] [Abstract][Full Text] [Related]
7. [Hepatocellular carcinoma].
Kondo S; Ueno H; Morizane C; Okusaka T
Gan To Kagaku Ryoho; 2010 Jul; 37(7):1219-23. PubMed ID: 20647702
[TBL] [Abstract][Full Text] [Related]
8. Adaptive randomized phase II design for biomarker threshold selection and independent evaluation.
Renfro LA; Coughlin CM; Grothey AM; Sargent DJ
Chin Clin Oncol; 2014 Mar; 3(1):3. PubMed ID: 25842081
[TBL] [Abstract][Full Text] [Related]
9. A Proposal for Progression-Free Survival Assessment in Patients with Early Progressive Cancer.
Tanase T; Hamada C; Yoshino T; Ohtsu A
Anticancer Res; 2017 Oct; 37(10):5851-5855. PubMed ID: 28982911
[TBL] [Abstract][Full Text] [Related]
10. Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma.
Vora SR; Zheng H; Stadler ZK; Fuchs CS; Zhu AX
Oncologist; 2009 Jul; 14(7):717-25. PubMed ID: 19581525
[TBL] [Abstract][Full Text] [Related]
11. The beta2-adrenergic receptor is a potential prognostic biomarker for human hepatocellular carcinoma after curative resection.
Chen D; Xing W; Hong J; Wang M; Huang Y; Zhu C; Yuan Y; Zeng W
Ann Surg Oncol; 2012 Oct; 19(11):3556-65. PubMed ID: 22588469
[TBL] [Abstract][Full Text] [Related]
12. Time-to-event analysis with treatment arm selection at interim.
Di Scala L; Glimm E
Stat Med; 2011 Nov; 30(26):3067-81. PubMed ID: 21898523
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma.
Personeni N; Bozzarelli S; Pressiani T; Rimassa L; Tronconi MC; Sclafani F; Carnaghi C; Pedicini V; Giordano L; Santoro A
J Hepatol; 2012 Jul; 57(1):101-7. PubMed ID: 22414760
[TBL] [Abstract][Full Text] [Related]
14. Cystine/glutamic acid transporter is a novel marker for predicting poor survival in patients with hepatocellular carcinoma.
Kinoshita H; Okabe H; Beppu T; Chikamoto A; Hayashi H; Imai K; Mima K; Nakagawa S; Ishimoto T; Miyake K; Yokoyama N; Ishiko T; Baba H
Oncol Rep; 2013 Feb; 29(2):685-9. PubMed ID: 23229496
[TBL] [Abstract][Full Text] [Related]
15. A two-stage Bayesian design for co-development of new drugs and companion diagnostics.
Karuri SW; Simon R
Stat Med; 2012 May; 31(10):901-14. PubMed ID: 22238151
[TBL] [Abstract][Full Text] [Related]
16. A Bayesian predictive strategy for an adaptive two-stage design in phase II clinical trials.
Sambucini V
Stat Med; 2010 Jun; 29(13):1430-42. PubMed ID: 20099246
[TBL] [Abstract][Full Text] [Related]
17. Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology.
Brannath W; Zuber E; Branson M; Bretz F; Gallo P; Posch M; Racine-Poon A
Stat Med; 2009 May; 28(10):1445-63. PubMed ID: 19266565
[TBL] [Abstract][Full Text] [Related]
18. Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib.
Nakazawa T; Hidaka H; Takada J; Okuwaki Y; Tanaka Y; Watanabe M; Shibuya A; Minamino T; Kokubu S; Koizumi W
Eur J Gastroenterol Hepatol; 2013 Jun; 25(6):683-9. PubMed ID: 23395995
[TBL] [Abstract][Full Text] [Related]
19. [The value of portal vein chemotherapy after radical resection in delaying intrahepatic recurrence of stage II primary hepatocellular carcinoma].
Zhang GQ; Ge L; Ding W; Li HJ
Ai Zheng; 2008 Dec; 27(12):1297-301. PubMed ID: 19079997
[TBL] [Abstract][Full Text] [Related]
20. Potential role of leptin expression in hepatocellular carcinoma.
Wang SN; Yeh YT; Yang SF; Chai CY; Lee KT
J Clin Pathol; 2006 Sep; 59(9):930-4. PubMed ID: 16565221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
